{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:55:34Z","timestamp":1792652134246,"version":"4.5.0"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"3","funder":[{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA201380"],"award-info":[{"award-number":["CA201380"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA055349"],"award-info":[{"award-number":["CA055349"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA192937"],"award-info":[{"award-number":["CA192937"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA008748"],"award-info":[{"award-number":["CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA178765"],"award-info":[{"award-number":["CA178765"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>CREBBP mutations are highly recurrent in B-cell lymphomas and either inactivate its histone acetyltransferase (HAT) domain or truncate the protein. Herein, we show that these two classes of mutations yield different degrees of disruption of the epigenome, with HAT mutations being more severe and associated with inferior clinical outcome. Genes perturbed by CREBBP mutation are direct targets of the BCL6\u2013HDAC3 onco-repressor complex. Accordingly, we show that HDAC3-selective inhibitors reverse CREBBP-mutant aberrant epigenetic programming, resulting in: (i) growth inhibition of lymphoma cells through induction of BCL6 target genes such as CDKN1A and (ii) restoration of immune surveillance due to induction of BCL6-repressed IFN pathway and antigen-presenting genes. By reactivating these genes, exposure to HDAC3 inhibitors restored the ability of tumor-infiltrating lymphocytes to kill DLBCL cells in an MHC class I and II\u2013dependent manner, and synergized with PD-L1 blockade in a syngeneic model in vivo. Hence, HDAC3 inhibition represents a novel mechanism-based immune epigenetic therapy for CREBBP-mutant lymphomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>We have leveraged the molecular characterization of different types of CREBBP mutations to define a rational approach for targeting these mutations through selective inhibition of HDAC3. This represents an attractive therapeutic avenue for targeting synthetic vulnerabilities in CREBBP-mutant cells in tandem with promoting antitumor immunity.<\/jats:p>\n                    <jats:p>This article is highlighted in the In This Issue feature, p. 327<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-19-0116","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T13:55:12Z","timestamp":1578491712000},"page":"440-459","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":148,"title":["Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma"],"prefix":"10.1158","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-3757","authenticated-orcid":false,"given":"Patrizia","family":"Mondello","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2887-6122","authenticated-orcid":false,"given":"Saber","family":"Tadros","sequence":"additional","affiliation":[{"name":"2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9415-1659","authenticated-orcid":false,"given":"Matt","family":"Teater","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1021-3654","authenticated-orcid":false,"given":"Lorena","family":"Fontan","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7770-7405","authenticated-orcid":false,"given":"Aaron Y.","family":"Chang","sequence":"additional","affiliation":[{"name":"3Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Jain","sequence":"additional","affiliation":[{"name":"2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haopeng","family":"Yang","sequence":"additional","affiliation":[{"name":"2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailbala","family":"Singh","sequence":"additional","affiliation":[{"name":"4Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsia-Yuan","family":"Ying","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Shuen","family":"Chu","sequence":"additional","affiliation":[{"name":"5Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2000-8144","authenticated-orcid":false,"given":"Man Chun John","family":"Ma","sequence":"additional","affiliation":[{"name":"2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eneda","family":"Toska","sequence":"additional","affiliation":[{"name":"6Department of Human Oncology and Pathogenesis, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Alig","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Durant","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"de Stanchina","sequence":"additional","affiliation":[{"name":"8Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreejoyee","family":"Ghosh","sequence":"additional","affiliation":[{"name":"2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Mottok","sequence":"additional","affiliation":[{"name":"9Institute of Pathology, University of W\u00fcrzburg and Comprehensive Cancer Center Mainfranken, W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0987-7373","authenticated-orcid":false,"given":"Oliver","family":"Weigert","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Inghirami","sequence":"additional","affiliation":[{"name":"10Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Baselga","sequence":"additional","affiliation":[{"name":"5Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"11Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4429-7307","authenticated-orcid":false,"given":"Cassian","family":"Yee","sequence":"additional","affiliation":[{"name":"4Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[{"name":"12Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Scheinberg","sequence":"additional","affiliation":[{"name":"3Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3865-8572","authenticated-orcid":false,"given":"Robert G.","family":"Roeder","sequence":"additional","affiliation":[{"name":"5Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8074-2287","authenticated-orcid":false,"given":"Ari M.","family":"Melnick","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Green","sequence":"additional","affiliation":[{"name":"2Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"13Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"14Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"2022060622250834500_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.molmed.2014.03.001","article-title":"Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis","volume":"20","author":"Hatzi","year":"2014","journal-title":"Trends Mol Med"},{"key":"2022060622250834500_bib2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.immuni.2016.09.001","article-title":"Germinal center B cell dynamics","volume":"45","author":"Mesin","year":"2016","journal-title":"Immunity"},{"key":"2022060622250834500_bib3","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.celrep.2013.06.016","article-title":"A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters","volume":"4","author":"Hatzi","year":"2013","journal-title":"Cell Rep"},{"key":"2022060622250834500_bib4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41590-018-0273-1","article-title":"Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis","volume":"20","author":"Hatzi","year":"2019","journal-title":"Nat Immunol"},{"key":"2022060622250834500_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ccell.2016.07.006","article-title":"EZH2 and BCL6 cooperate to assemble CBX8-BCOR complex to repress bivalent promoters, mediate germinal center formation and lymphomagenesis","volume":"30","author":"Beguelin","year":"2016","journal-title":"Cancer Cell"},{"key":"2022060622250834500_bib6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","article-title":"Chromatin modifying gene mutations in follicular lymphoma","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"key":"2022060622250834500_bib7","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060622250834500_bib8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2159-8290.CD-16-0975","article-title":"CREBBP inactivation promotes the development of HDAC3-dependent lymphomas","volume":"7","author":"Jiang","year":"2017","journal-title":"Cancer Discov"},{"key":"2022060622250834500_bib9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.immuni.2007.07.009","article-title":"Germinal-center organization and cellular dynamics","volume":"27","author":"Allen","year":"2007","journal-title":"Immunity"},{"key":"2022060622250834500_bib10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nature21433","article-title":"Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens","volume":"543","author":"Khodadoust","year":"2017","journal-title":"Nature"},{"key":"2022060622250834500_bib11","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood-2018-06-845156","article-title":"B cell lymphomas present immunoglobulin neoantigens","volume":"133","author":"Khodadoust","year":"2019","journal-title":"Blood"},{"key":"2022060622250834500_bib12","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.cell.2018.08.048","article-title":"Evolutionary pressure against MHC class II binding cancer mutations","volume":"175","author":"Marty","year":"2018","journal-title":"Cell"},{"key":"2022060622250834500_bib13","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1182\/blood-2003-07-2365","article-title":"Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project","volume":"103","author":"Rimsza","year":"2004","journal-title":"Blood"},{"key":"2022060622250834500_bib14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","article-title":"MHC-II neoantigens shape tumour immunity and response to immunotherapy","volume":"574","author":"Alspach","year":"2019","journal-title":"Nature"},{"key":"2022060622250834500_bib15","doi-asserted-by":"crossref","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci Transl Med"},{"key":"2022060622250834500_bib16","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"2022060622250834500_bib17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"2022060622250834500_bib18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4(+) T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2022060622250834500_bib19","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2016-08-733469","article-title":"Crebbp loss cooperates with Bcl2 over-expression to promote lymphoma in mice","volume":"129","author":"Garcia-Ramirez","year":"2017","journal-title":"Blood"},{"key":"2022060622250834500_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature09727","article-title":"CREBBP mutations in relapsed acute lymphoblastic leukaemia","volume":"471","author":"Mullighan","year":"2011","journal-title":"Nature"},{"key":"2022060622250834500_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"key":"2022060622250834500_bib22","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.1073\/pnas.1619555114","article-title":"Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth","volume":"114","author":"Hashwah","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060622250834500_bib23","doi-asserted-by":"crossref","first-page":"11093","DOI":"10.1038\/ncb3597","article-title":"Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors","volume":"19","author":"Horton","year":"2017","journal-title":"Nat Cell Biol"},{"key":"2022060622250834500_bib24","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1158\/2159-8290.CD-16-1417","article-title":"The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma","volume":"7","author":"Zhang","year":"2017","journal-title":"Cancer Discov"},{"key":"2022060622250834500_bib25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.immuni.2019.08.006","article-title":"Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma","volume":"51","author":"Meyer","year":"2019","journal-title":"Immunity"},{"key":"2022060622250834500_bib26","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"2022060622250834500_bib27","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1093\/emboj\/19.16.4342","article-title":"Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3","volume":"19","author":"Li","year":"2000","journal-title":"EMBO J"},{"key":"2022060622250834500_bib28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1021\/acschembio.5b00640","article-title":"An isochemogenic set of inhibitors to define the therapeutic potential of histone deacetylases in beta-cell protection","volume":"11","author":"Wagner","year":"2016","journal-title":"ACS Chem Biol"},{"key":"2022060622250834500_bib29","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/ni1245","article-title":"BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells","volume":"6","author":"Phan","year":"2005","journal-title":"Nat Immunol"},{"key":"2022060622250834500_bib30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.biomaterials.2015.09.007","article-title":"Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells","volume":"73","author":"Tian","year":"2015","journal-title":"Biomaterials"},{"key":"2022060622250834500_bib31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cell.2004.09.014","article-title":"MTA3 and the Mi-2\/NuRD complex regulate cell fate during B lymphocyte differentiation","volume":"119","author":"Fujita","year":"2004","journal-title":"Cell"},{"key":"2022060622250834500_bib32","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.celrep.2014.07.059","article-title":"The BCL6 RD2 domain governs commitment of activated B cells to form germinal centers","volume":"8","author":"Huang","year":"2014","journal-title":"Cell Rep"},{"key":"2022060622250834500_bib33","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/emboj.2010.136","article-title":"Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis","volume":"29","author":"Wilting","year":"2010","journal-title":"EMBO J"},{"key":"2022060622250834500_bib34","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"2022060622250834500_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"2022060622250834500_bib36","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1182\/blood-2005-08-3263","article-title":"Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells","volume":"107","author":"Xu","year":"2006","journal-title":"Blood"},{"key":"2022060622250834500_bib37","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-017-01029-x","article-title":"EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop","volume":"8","author":"Beguelin","year":"2017","journal-title":"Nat Commun"},{"key":"2022060622250834500_bib38","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-16-1189","article-title":"BCL6 antagonizes NOTCH2 to maintain survival of human follicular lymphoma cells","volume":"7","author":"Valls","year":"2017","journal-title":"Cancer Discov"},{"key":"2022060622250834500_bib39","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1172\/JCI85795","article-title":"Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma","volume":"126","author":"Cardenas","year":"2016","journal-title":"J Clin Invest"},{"key":"2022060622250834500_bib40","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"key":"2022060622250834500_bib41","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cell.2016.03.031","article-title":"Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling","volume":"165","author":"Minn","year":"2016","journal-title":"Cell"},{"key":"2022060622250834500_bib42","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.12819","article-title":"A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"165","author":"Ogura","year":"2014","journal-title":"Br J Haematol"},{"key":"2022060622250834500_bib43","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/annonc\/mdn031","article-title":"Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma","volume":"19","author":"Crump","year":"2008","journal-title":"Ann Oncol"},{"key":"2022060622250834500_bib44","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-11-0482","article-title":"The two faces of interferon-gamma in cancer","volume":"17","author":"Zaidi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022060622250834500_bib45","doi-asserted-by":"crossref","first-page":"704","DOI":"10.4049\/jimmunol.1800876","article-title":"BCL6-mediated silencing of PD-1 ligands in germinal center B cells maintains follicular T cell population","volume":"202","author":"Peng","year":"2019","journal-title":"J Immunol"},{"key":"2022060622250834500_bib46","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat Protoc"},{"key":"2022060622250834500_bib47","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2016.03.008","article-title":"The public repository of xenografts enables discovery and randomized phase II-like trials in mice","volume":"29","author":"Townsend","year":"2016","journal-title":"Cancer Cell"},{"key":"2022060622250834500_bib48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.biomaterials.2015.06.002","article-title":"Ex vivo engineered immune organoids for controlled germinal center reactions","volume":"63","author":"Purwada","year":"2015","journal-title":"Biomaterials"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/10\/3\/440\/1813368\/440.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/10\/3\/440\/1813368\/440.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T18:25:49Z","timestamp":1654539949000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/10\/3\/440\/2616\/Selective-Inhibition-of-HDAC3-Targets-Synthetic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,1]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,3]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-19-0116","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.22535296","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22535293","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22535293.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22535296.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6547819","asserted-by":"object"},{"id-type":"doi","id":"10.1101\/531954","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6547819.v1","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,1]]}}}